GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Nutex Health Inc (NAS:NUTX) » Definitions » Peter Lynch Fair Value

Nutex Health (Nutex Health) Peter Lynch Fair Value : N/A (As of May. 24, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nutex Health Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Nutex Health's Peter Lynch Fair Value or its related term are showing as below:



NUTX's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.34
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Nutex Health Peter Lynch Fair Value Historical Data

The historical data trend for Nutex Health's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutex Health Peter Lynch Fair Value Chart

Nutex Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
- - - - -

Nutex Health Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nutex Health's Peter Lynch Fair Value

For the Health Information Services subindustry, Nutex Health's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nutex Health's Price-to-Peter-Lynch-Fair-Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Nutex Health's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Nutex Health's Price-to-Peter-Lynch-Fair-Value falls into.



Nutex Health Peter Lynch Fair Value Calculation

Nutex Health's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-0.435
=N/A

Nutex Health's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was $-0.44.

* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Nutex Health  (NAS:NUTX) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Nutex Health's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.7456/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nutex Health Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Nutex Health's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Nutex Health (Nutex Health) Business Description

Traded in Other Exchanges
N/A
Address
6030 S. Rice Ave, Suite C, Houston, TX, USA, 77081
Nutex Health Inc is healthcare services and operations company with 19 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.
Executives
Thomas T. Vo director, officer: Chairman, CEO 6030 S. RICE AVE., SUITE C, HOUSTON TX 77081
Joshua Detillio officer: Chief Operating Officer 6030 S. RICE AVENUE, SUITE C, HOUSTON TX 77081
Jon Christian Bates officer: Chief Financial Officer 6030 S. RICE AVE., SUITE C, HOUSTON TX 77081
Mitchell Creem director 700 NORTH BRAND BLVD., SUITE 450, GLENDALE CA 91203
Pamela W. Montgomery officer: Chief Legal Off. & Secretary 6030 S. RICE AVE., SUITE C, HOUSTON TX 77081
Michael Lee Reed director 6030 S. RICE AVE., SUITE C, HOUSTON TX 77081
Cheryl Yvonne Grenas director 6030 S. RICE AVE., SUITE C, HOUSTON TX 77081
John J Waters director 2165 TECHNOLOGY DRIVE, SCHENECTADY NY 12308
Danniel Stites director 3050 S. DOBSON ROAD, CHANDLER AZ 85248
Premier Macy Management Holdings, Llc 10 percent owner 2819 CYPRESS DRIVE, TEXARKANA TX 75503
Michael Bowen officer: Chief Financial Officer 501 1ST AVENUE NORTH, SUITE 901, ST. PETERSBURG FL 33701
Warren Hosseinion director C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Lawrence Schimmel officer: Chief Medical Information Off 5193 SW 75TH STREET, MIAMI FL 33143
Frederick Sternberg officer: President of subsidiary 10772 SANDY RUN RD, JUPTIER FL 33478
Micro Hospital Holding Llc 10 percent owner 6030 S. RICE AVE., SUITE C, HOUSTON TX 77081